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“Malaria is ... like chess, it is played with a few pieces, but is capable of an infinite variety of 
situations” L. Hackett, 1937 (1) 
 
After a decade of declining numbers of malaria cases in many endemic areas, the threat of 
travelers’ malaria appeared to diminish and the perceived risk of acquiring malaria during 
travel paled in comparison to other mosquito-borne infections.  However, the latest 2018 
world malaria report shows an increase in the global total of malaria cases: in 2017, an 
estimated 219 million cases of malaria occurred worldwide (95% confidence interval [CI]: 
203–262 million), compared with 217 million cases in 2016 (95% CI: 200–259 million). Some 
92% (approximately 200 million) of the 2017 cases were in the WHO African Region (2).  
 
Like endemic malaria, imported malaria is a complex epidemiological puzzle. In our agile, 
interconnected, global community with an unprecedented 1.3 billion tourist arrivals per 
annum, including approximately 41 million tourist arrivals in Sub-Saharan Africa in 2017 (3), 
it is par for the course that large numbers of imported malaria cases will be seen and 
reported in industrialized countries like the United Kingdom (UK), that are classified 
“malaria free”. 
Many countries mandate reporting of malaria cases and the UK has an effective reporting 
system under the auspices of the Malaria Reference Laboratory reporting over 1500 cases 
per year. The main risk group identified in the national malaria statistics is the “visiting 
friends and relatives” (VFR) African group who visit their country of origin. This finding 
reflects the findings of the WHO global malaria situation report showing that 92% of malaria 
cases occur in Africa, particularly in West Africa. The VFR traveller group has been shown to 
have poor uptake of malaria chemoprophylaxis which is likely to be due to a number of 
factors including this group not seeking or not able to access malaria prevention advice prior 
to travel, or not being given good advice, or not adhering to it.  Additionally their perception 
of risk may be lower as they are travelling to a country that is familiar to them, and the cost 
of chemoprophylaxis may also be a prohibitive factor (4).   
National surveillance is never perfect, even for the UK data it is estimated that this enhanced 
surveillance system still only captures 56% of cases in England (5) and may not include cases that 
were diagnosed and/or treated abroad. Certain key data variables are often missing in national 
statistics. These include details such as exposition type, itinerary, chemoprophylaxis use – or lack 
thereof, adherence to preventive measures and details concerning presentation and course of the 
malaria infection. Nevertheless, information, data and trends in imported malaria are key to 
formulating prevention guidelines and recommendations for travel medicine practitioners (6). 
 
The paper from Moyo et al. (7) in this issue evaluated, in detail, 225 cases of imported malaria 
treated at Addenbrooke’s hospital, Cambridge, England and placed these cases in the context of 
imported malaria in the UK. The area of acquisition of most cases of malaria, in their study, was 
Africa, particularly West Africa. Their single center results reflect the overall national epidemiology 
of imported malaria but bring a new twist in that they stress that the prevention focus should not 
just be on VFR travelers but also on those traveling for work and tourism to Africa. The numbers of 
imported malaria cases in the latter two groups combined exceed the VFR group. The Cambridge 
paper also highlights that malaria chemoprophylaxis uptake in occupational and tourist travelers to 
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Africa is low.  This may of course reflect the demographics of travelers in the Cambridge area, but 
does not detract from the fact that some 60% of the malaria patients in this collective, took no 
chemoprophylaxis at all despite travel to high risk, malaria endemic areas. This publication also 
shows a case fatality rate (CFR) of 1.5%, distinctly higher than the UK national CFR of 0.4% for 
imported malaria.  
 
We know the risk groups (VFR, occupational and tourist travelers) and the risk areas (principally 
African) and we have the chemoprophylaxis and mosquito bite prevention tools to prevent travelers 
malaria so how can we move forward in what seems to be a travel medicine malaria stalemate?  It 
would appear advisable to increase access to malaria chemoprophylaxis for all travelers to Africa 
and here the UK has made major changes, that have been incorporated in the current UK malaria 
prevention guidelines (6). Some effective malaria chemoprophylaxis such as the combination 
atovaquone/proguanil is now available without prescription in UK pharmacies (8) and this will 
reduce the barrier to medication procurement. Use of malaria chemoprophylaxis by travelers to 
high-risk, malaria-endemic, African destinations has been shown to be an effective, travel medicine 
strategy to prevent malaria and malaria deaths regardless of whether the traveler is a VFR, business 
traveler or tourist (9). Malaria awareness in returning travelers and health services is also paramount 
so that malaria can be diagnosed and treated rapidly even in non-urban areas. Delays in diagnosis 
and treatment have been shown to be key risk factors for malaria deaths in the UK and elsewhere. 
A plan to reduce imported malaria in the UK must clearly have a twin focus on “travel” and “Africa”. 
While some of the preventive strategies will be relevant to all travelers irrespective of their reason 
for travel, Moyo and colleagues have highlighted that understanding the local context is essential, 
and that a ‘one-size fits all’ approach will not address the needs of different groups of travelers.  The 
challenge for travel health professionals will be not only to raise awareness, but also to understand 
their traveler population, their beliefs, and motivations, and their malaria importation patterns so 
they can truly engage with them and influence behavior and attitudinal changes. Could an effective 
health communication and social marketing- campaign with travel and airline partners “checkmate” 
imported malaria?    
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